CUREVAC N V's ticker is CVAC and the CUSIP is N2451R105. A total of 93 filers reported holding CUREVAC N V in Q4 2023. The put-call ratio across all filers is 0.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $83 | -89.3% | 24,356 | -90.5% | 0.00% | -83.3% |
| Q1 2024 | $773 | +842.7% | 255,164 | +1210.8% | 0.01% | +500.0% |
| Q4 2023 | $82 | -99.9% | 19,466 | +62.3% | 0.00% | -50.0% |
| Q2 2022 | $163,000 | -73.9% | 11,995 | -62.3% | 0.00% | -75.0% |
| Q1 2022 | $624,000 | -54.9% | 31,804 | +25.5% | 0.01% | -57.9% |
| Q3 2021 | $1,385,000 | +507.5% | 25,348 | +915.5% | 0.02% | +533.3% |
| Q1 2021 | $228,000 | -86.3% | 2,496 | -87.9% | 0.00% | -81.2% |
| Q4 2020 | $1,666,000 | – | 20,550 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 370,385 | $17,241,000 | 4.81% |
| Novo Holdings A/S | 201,642 | $9,386,000 | 0.47% |
| Vivo Capital, LLC | 169,825 | $7,905,000 | 0.46% |
| Baillie Gifford | 3,896,475 | $181,381,000 | 0.12% |
| DekaBank Deutsche Girozentrale | 435,500 | $21,707,000 | 0.10% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 69,176 | $3,220,000 | 0.08% |
| HHLR ADVISORS, LTD. | 186,183 | $8,667,000 | 0.07% |
| Pinz Capital Management, LP | 3,600 | $168,000 | 0.06% |
| Cutler Group LLC / CA | 18,400 | $856,000 | 0.05% |
| ETF MANAGERS GROUP, LLC | 35,722 | $1,632,000 | 0.05% |